Tribune Therapeutics
PrivateLast Round
Series A
Mar 26, 2025
Total Funding Raised
$56.99M
Company Overview
Tribune Therapeutics operates in Healthcare & Life Sciences and is based in Stockholm. Its latest recorded funding round was a Series A round in March 2025.
Tribune Therapeutics is a biotechnology company developing a pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tribune Therapeutics Comparables
Compare Tribune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Certa Therapeutics | 78% | |
| Mediar Therapeutics | 78% | |
| Ikaika Therapeutics | 73% |
For institutional investors. Book with your work email.
Tribune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 26, 2025 | ||||
| Seed | Jun 2, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tribune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovestor | Series A |
| Inven2 | Seed, Series A |
| Investinor | Series A |
| HealthCap | Series A, Seed |
| Industrifonden | Series A |
| Novo Holdings | Series A, Seed |
| LifeArc Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
Monthly visitors grew 99% MoM, reaching 1.2K.
- Mar 26, 2025
$40M raised in Seed round.
For institutional investors. Book with your work email.
Tribune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tribune Therapeutics's valuation, stock price, and market status.
Is Tribune Therapeutics a public or private company?
Tribune Therapeutics is a private company.
What is the current stock price of Tribune Therapeutics?
Tribune Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tribune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tribune Therapeutics worth (valuation)?
Valuation information for Tribune Therapeutics is not publicly available.
Can I buy Tribune Therapeutics stock?
Tribune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tribune Therapeutics's last funding round?
Tribune Therapeutics's most recent funding round was Series A on March 26, 2025.
Who are the main investors in Tribune Therapeutics?
Key investors in Tribune Therapeutics include HealthCap, Novo Holdings, LifeArc Ventures.
Will Tribune Therapeutics IPO soon?
No public IPO plans have been announced for Tribune Therapeutics.
How can I track Tribune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tribune Therapeutics's shares on secondary markets.